Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 2 of 2 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 2 of 2
The authors describe the importance of a rapid and an abbreviated screening strategy in initial solvent screening. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 6

References

1. A.L. Grzesiak et al., "Comparison of the Four Anhydrous Polymorphs of Carbamazepine and the Crystal Structure of Form I," J. Pharm. Sci. 92 (11), 2260–2271 (2003).

2. M.D. Tuladhar, J.E. Carless, and M. P. Summers, "Thermal Behavior and Dissolution Properties of Phenylbutazone Polymorphs," J. Pharm. Pharmacol. 35 (4), 208–214 (1983).

3. A. Bauer-Brandl, "Polymorphic Transitions of Cimetidine during Manufacture of Solid Dosage Forms," Int. J. Pharm. 140 (2), 195–206 (1996).

4. B. Hegedüs and S. Görög, "The Polymorphism of Cimetidine," J. Pharm. Biomed. Anal. 3 (4), 303–313 (1985).

5. A.M. Tudor et al., "The Applications of Near-Infrared Fourier Transform Raman Spectroscopy to the Analysis of Polymorphic Forms of Cimetidine," Spectrochim. Acta 47A (9–10), 1389–1393 (1991).

6. W.A. Bueno and E.G. Sobrinho, "Hydrogen Bonds in the Cimetidine Molecule," Spectrochim. Acta 51A (2), 287–292 (1995).

7. W.N. Richmond, P.W. Faguy, and S.C. Weibel, "An In Situ Infrared Spectroscopic Study of Imidazole Films on Copper Electrodes," J. Electroanal. Chem. 448 (2), 237–244 (1998).

8. G.J. Durant et al., "Cyanoguanidine-Thiourea Equivalence in the Development of the Histamine H2-Receptor Antagonist, Cimetidine," J. Med. Chem. 20 (7), 901–906 (1977).

9. T. Lee and S.T. Hung, "Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs," Pharm. Technol. 32 (1), 76–95 (2008).

10. C.C. Chen and P.A. Crafts, "Correlation and Prediction of Drug Molecule Solubility in Mixed Solvent Systems with the Nonrandom Two-Liquid Segment Activity Coefficient (NRTL-SAC) Model," Ind. Eng. Chem. Res. 45 (13), 4816–4824 (2006).

11. A. Getsoian, R.M. Lodaya, and A.C. Blackburn, "One-Solvent Polymorph Screen of Carbamazepine," Int. J. Pharm. 348 (1–2), 3–9 (2008).

12. T. Lee, Y.H. Chen, and C.W. Zhang, "Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R,S)-(±)-Sodium Ibuprofen Dihydrate," Pharm. Technol. 31 (6), 72–87 (2007).

13. C. Rey-Mermet et al., "Significance of Partial and Total Cohesion Parameters of Pharmaceutical Solids Determined from Dissolution Calorimetric Measurements," Pharm. Res. 8 (5), 636–642 (1991)."

14. T. Lee, C.S. Kuo, and Y.H. Chen, "Solubility, Polymorphism, Crystallinity, and Crystal Habit of Acetaminophen and Ibuprofen," Pharm. Technol. 30 (10), 72–92 (2006).

15. T. Hosokawa et al., "Relationships between Crystal Structures and Thermodynamic Properties of Phenylbutazone Solvates," Cryst. Eng. Comm. 6 (44), 243–249 (2004).

16. T. Lee and M.S. Lin, "Sublimation Point Depression of Tris(8-hydroxyquinoline)aluminum(III) (Alq3) by Crystal Engineering," Cryst. Growth Des. 7 (9), 1803–1810 (2007).

17. Y. Kobayashi et al., "Physicochemical Properties and Bioavailability of Carbamazepine Polymorphs and Dihydrate," Int. J. Pharm. 193 (2), 137–146 (2000).

18. R. Hilfiker et al., "Polymorphism—Integrated Approach from High-Throughput Screening to Crystallization Optimization," J. Therm. Anal. Calorim. 73 (2) 429–440 (2003).

19. S.G. Fleischman et al., "Crystal Engineering of the Composition of Pharmaceutical Phases: Multiple-Component Crystalline Solids Involving Carbamazepine," Cryst. Growth Des. 3 (6), 909–919 (2003).

20. M.M.J. Lowes et al., "Physicochemical Properties and X-ray Structural Studies of the Trigonal Polymorph of Carbamazepine," J. Pharm. Sci. 76 (9), 744–752 (1987).

21. C. Rustichelli et al., "Solid-State Study of Polymorphic Drugs: Carbamazepine," J. Pharm. Biomed. Anal. 23 (1), 41–54 (2000).

22. J. Bernstein, R.J. Davey, and J.O. Henck, "Concomitant Polymorphs," Angew. Chem. Int. Ed. 38 (23), 3440–3461 (1999).

23. S. Sudo, K. Sato, and Y. Harano, "Solubilities and Crystallization Behavior of Cimetidine Polymorphic Forms A and B," Japan. J. Chem. Eng. 24 (2), 237–242 (1991).

24. H.H. Paradies, "Structure of Phenylbutazone and Mofebutazone in the Crystalline State and in Solution," J. Pharm. Sci. 76 (12), 920–929 (1987).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here